New Drug Discovery in Hematology
Advancing novel therapeutic agents for the treatment of malignancy into the marketplace is an increasingly costly and lengthy process. As such, new strategies for drug discovery are needed. Drug repurposing represents an opportunity to rapidly advance new therapeutic strategies into clinical trials at a relatively low cost. Known on-patent or off-patent drugs with unrecognized anticancer activity can be rapidly advanced into clinical testing for this new indication by leveraging their known pharmacology, pharmacokinetics, and toxicology. Using this approach, academic groups can participate in the drug discovery field and smaller biotechnology companies can “de-risk” early-stage drug discovery projects. Here, several scientific approaches used to identify drug repurposing opportunities are highlighted, with a focus on hematologic malignancies. In addition, a discussion of the regulatory issues that are unique to drug repurposing and how they impact developing old drugs for new indications is included. Finally, the mechanisms to enhance drug repurposing through increased collaborations between academia, industry, and non-profit charitable organizations are discussed.
Coronavirus Conference | Covid-19 Pandemic | Latest invention and Researches on Covid-19 | World Infectious Diseases 2021
- Hematopoietic Cells Mobilization
- Patient-reported outcomes in drug development
- De novo drug discovery
- Clinical trials
Related Conference of New Drug Discovery in Hematology
New Drug Discovery in Hematology Conference Speakers
Recommended Sessions
- Bacterial Infectious Diseases
- Blood and Hematology
- Blood transfusion
- Corona Virus Diseases
- Diagnosis, Treatment and Management of Blood disorders
- Hematology and neurological disorders
- Mycobacterial infections
- Pathogenic infections
- Respiratory infectious diseases
- Animal vaccination
- Antigen-antibody reactions
- Aspects of plant bacteriology
- Biomarkers in Hematology
- Blood disorders
- Chickenpox
- Diagnosis and treatment
- Effect of Advanced Technologies on Blood Based Products
- Epidemiology
- Food infections
- Hematologic Therapies
- Lower respiratory tract infection
- New Drug Discovery in Hematology
- Reproductive infectious diseases
- Sexually transmitted diseases
- Tuberculosis
Related Journals
Are you interested in
- Bleeding Disorders in Women - Blood Disorders 2024 (Ireland)
- Digital Health and Artificial Intelligence (AI) in Hematology - Blood Disorders 2024 (Ireland)
- Hematologic Gene Editing and Gene Therapies - Blood Disorders 2024 (Ireland)
- Hematology and Stem Cell Research - Blood Disorders 2024 (Ireland)
- Hematopoietic Stem Cell Transplantation - Blood Disorders 2024 (Ireland)
- Hemoglobinopathies and Sickle Cell Disease - Blood Disorders 2024 (Ireland)
- Hemophilia Management and Research - Blood Disorders 2024 (Ireland)
- Hemostasis and Thrombosis - Blood Disorders 2024 (Ireland)
- Immunotherapy and Hematology - Blood Disorders 2024 (Ireland)
- Leukemia and Lymphoma - Blood Disorders 2024 (Ireland)
- Medicine in Hematology - Blood Disorders 2024 (Ireland)
- Molecular Hematology - Blood Disorders 2024 (Ireland)
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure - Blood Disorders 2024 (Ireland)
- Next-Generation Diagnostics and Imaging - Blood Disorders 2024 (Ireland)
- Novel Therapies for Blood Cancers - Blood Disorders 2024 (Ireland)
- Pediatric Hematology - Blood Disorders 2024 (Ireland)
- Platelet Disorders - Blood Disorders 2024 (Ireland)
- Sickle Cell Disease (SCD) - Blood Disorders 2024 (Ireland)
- Thalassemia Management - Blood Disorders 2024 (Ireland)
- Transfusion Medicine and Blood Banking - Blood Disorders 2024 (Ireland)